Prostate specific antigen(PSA)からみた前立腺癌の診断と治療

Abstract

国際標準化とgray zone症例の意義について検討した.従来のデータを生かした標準値への転換式の提案とgray zoneの予後が良好であることが判明した.このため効率良い診断手段, とりわけmolecular form測定の意義に関する検討が必要であろうと考えた

An international standard of prostate specific antigen (PSA) assays was constructed and prognosis of the patients with prostate cancers showing gray zone PSA was studied. For lower levels of serum PSA (< 50 ng/ml), the conversion formula to that of Tandem-R PSA from other assays was presented. Furthermore, based on the standards of Stanford Reference and Markit-MPA, conversion rates to this international standard from the conventional PSA assays were also obtained. Patients' cancer-specific survival was found to be significantly better in the gray zone group. Further studies to obtain higher specificity such as using free or complex rate in total PSA is necessary.